Arrowhead Reports Fiscal 2013 First Quarter Financial Results

  Arrowhead Reports Fiscal 2013 First Quarter Financial Results

              - Conference Call Today at 4:30 p.m. Eastern Time

Business Wire

PASADENA, Calif. -- February 13, 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics
company, today announced financial results for its fiscal 2013 first quarter
ended December 31, 2012. The company is hosting a conference call at 4:30 p.m.
Eastern time (1:30 p.m. Pacific time) to discuss results. To participate,
please dial 877-317-6789 (toll free from the US), 866-605-3852 (toll free from
Canada), or 412-317-6789 (for international callers). Investors may also
access a live audio webcast of this conference call on the Company's website

"Fiscal 2012 was a productive building year for Arrowhead as we acquired
substantial RNAi assets and the world’s largest human-derived peptide
targeting library," said Dr. Christopher Anzalone, President and Chief
Executive Officer. "We are now in a position to begin demonstrating the value
of these programs in 2013. This means entering the clinic with what we believe
to be a potential breakthrough hepatitis B treatment; continuing clinical
studies in our obesity program; building new clinical candidates; publishing
data demonstrating the power of our platforms and candidates; and entering
into new collaborations and partnerships. As such, we achieved some key
milestones in the first fiscal quarter and expect to achieve significant
milestones throughout the year."

Fiscal 2013 First Quarter and Recent Company Highlights

  *Program and Pipeline Highlights

       *Advanced manufacturing and GLP toxicology studies of ARC-520, with
         regulatory filing expected in Q2 2013 to begin first-in-man studies;
       *Presented data at multiple scientific conferences including data on
         new DPC subcutaneous formulation showing 99% target gene knockdown in
         non-human primates without observed toxicity;
       *Published studies in the journal Nucleic Acid Therapeutics
         demonstrating high levels of knockdown in non-human primates using
         cholesterol-conjugated siRNA, DPCs, and a novel co-injection
       *Received additional patents on the DPC siRNA delivery system;
       *Established a Clinical Advisory Board for hepatitis B including
         prominent hepatologist Dr. Robert G. Gish;

  *Business Development Highlights

       *Entered into a Collaboration and License Agreement with Shire for
         peptide-targeted therapeutics that includes research funding for
         Arrowhead, up to $32.8 million in potential milestone payments, and
         royalties on sales;

  *Financial Highlights

       *Strengthened the balance sheet through equity financings with gross
         proceeds of $7.5 million.

Selected Fiscal 2013 First Quarter Financial Results

Total operating expenses for the quarter ended December 31, 2012 were $5.0
million, compared to $4.1 million during the quarter ended December 31, 2011.

Net loss attributable to Arrowhead for the quarter ended December 31, 2012 was
$4.6 million, or $0.33 per share based on 14.1 million weighted average shares
outstanding. This compares with a net loss attributable to Arrowhead of $2.5
million, or $0.25 per share based on 10.1 million weighted average shares
outstanding, for the quarter ended December 31, 2011.

During the three months ended December 31, 2012, net cash used in operating
activities was $3.8 million, compared to $2.7 million during the prior year

The company’s cash position was $2.9 million at December 31, 2012, compared to
$3.4 million at September 30, 2012. During the quarter, the cash decrease of
$0.5 million was due to operating cash flow of $3.8 million offset by cash
flow from financing activities of $3.3 million. During January an additional
financing yielded net proceeds of $3.3 million.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics
company with development programs in oncology, obesity, and chronic hepatitis
B virus infection. The company is leveraging its platform technologies to
design and develop peptide-drug conjugates (PDCs) that specifically home to
cell types of interest while sparing off-target tissues, create targeted drugs
based on the gene silencing RNA interference (RNAi) mechanism, and work with
partners to create improved versions of traditional small molecule drugs.

For more information please visit, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as a result
of various factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our ability to
successfully develop drug candidates, the timing for starting and completing
clinical trials, rapid technological change in our markets, and the
enforcement of our intellectual property rights. Arrowhead Research
Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We assume
no obligation to update or revise forward-looking statements to reflect new
events or circumstances.


Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Lauren Glaser
Press spacebar to pause and continue. Press esc to stop.